Larson Yi
Insider CIK 1785987 · TPTX EVP & Chief Financial Officer · OLMA Director · RYZB Director · LIAN Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| RYZB RayzeBio, Inc. | D To issuer deriv | 2024-02-26 | 2024-02-27 | 40,848 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | D To issuer deriv | 2024-02-26 | 2024-02-27 | 59,399 | — | $0 | 0 | SEC↗ |
| RYZB RayzeBio, Inc. | D To issuer deriv | 2024-02-26 | 2024-02-27 | 14,332 | — | $0 | 0 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| LIAN LianBio | A Award | 2023-03-29 | 2023-03-31 | 325,901 | — | $0 | 325,901 | SEC↗ |
| LIAN LianBio | A Award deriv | 2023-01-20 | 2023-01-24 | 464,099 | — | $0 | 464,099 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| LIAN LianBio | A Award deriv | 2021-12-01 | 2021-12-03 | 5,996 | — | $0 | 1,202,841 | SEC↗ |
| LIAN LianBio | A Award deriv | 2021-10-31 | 2021-11-01 | 229,538 | — | $0 | 1,196,845 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2021-06-09 | 2021-06-10 | 21,520 | — | $0 | 21,520 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2021-04-05 | 2021-04-06 | 21,520 | — | $0 | 21,520 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | A Award deriv | 2021-04-05 | 2021-04-06 | 3,773 | — | $0 | 3,773 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2021-02-08 | 2021-02-10 | 20,775 | — | $0 | 20,775 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award | 2021-02-08 | 2021-02-10 | 4,617 | — | $0 | 7,321 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise deriv | 2021-02-02 | 2021-02-02 | 14,298 | — | $0 | 282,397 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-02 | 2021-02-02 | 400 | $128.41 | $51.4K | 15,602 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-02 | 2021-02-02 | 1,000 | $127.58 | $127.6K | 16,002 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise | 2021-02-02 | 2021-02-02 | 14,298 | $54.03 | $772.5K | 17,002 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-02 | 2021-02-02 | 1,057 | $131.73 | $139.2K | 2,704 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-02 | 2021-02-02 | 7,267 | $130.58 | $948.9K | 3,761 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-02 | 2021-02-02 | 4,574 | $129.80 | $593.7K | 11,028 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise deriv | 2021-02-01 | 2021-02-02 | 15,702 | — | $0 | 296,695 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-01 | 2021-02-02 | 200 | $126.07 | $25.2K | 2,704 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-01 | 2021-02-02 | 2,143 | $124.60 | $267.0K | 2,904 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-01 | 2021-02-02 | 8,576 | $123.70 | $1.06M | 5,047 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-02-01 | 2021-02-02 | 4,783 | $122.94 | $588.0K | 13,623 | SEC↗ |
| TPTX Turning Point Therapeutics | M Exercise | 2021-02-01 | 2021-02-02 | 15,702 | $54.03 | $848.4K | 18,406 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2020-01-06 | 2020-01-08 | 33,000 | — | $0 | 33,000 | SEC↗ |
| TPTX Turning Point Therapeutics | P Buy | 2019-09-10 | 2019-09-11 | 2,222 | $45.00 | $100.0K | 2,222 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2019-08-26 | 2019-08-27 | 312,397 | — | $0 | 312,397 | SEC↗ |